



Published in final edited form as:

Obstet Gynecol. 2023 August 01; 142(2): 429. doi:10.1097/AOG.0000000000005273.

Perinatal Outcomes After Bariatric Surgery Compared With a Matched Control Group

Jacob C. Kahrs, MPH,

Kimi Van Wickle, MSPH,

Michelle T. Delahanty, MPH,

Mollie E. Wood, PhD, MPH

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

We appreciate the study from Boller et al¹ in the March 2023 issue on perinatal outcomes after bariatric surgery. This topic is of interest because bariatric surgery has been shown to significantly reduce obesity-related comorbidities through sustained weight loss, but it is understudied in the context of pregnancy.^{2,3} However, ambiguities in the treatment definition make it difficult to translate these results into clinical practice.

In this study, bariatric surgery is well-defined, and the authors stratify analyses to consider variation by procedure type. However, those in the no-surgery group are potentially participating in a variety of other undefined and unmeasured weight-loss regimens (eg, lifestyle modifications, therapy, medication, a combination of these regimens, or no weight-loss treatment at all). This group includes people who may be eligible for bariatric surgery and those who are not. This results in difficulties with clinical interpretation because we cannot properly attribute the estimates to bariatric surgery.⁴ For example, comparing bariatric surgery with semaglutide would likely produce a different estimate than comparing surgery with psychotherapy, but neither of these alternative treatments are measured in the current study.

By ignoring other types of weight-loss treatment, the authors implicitly assume that the distribution and effect of these alternative treatments are balanced between those who did and did not undergo surgery. The distribution of alternative treatments likely differs between these groups, because bariatric surgery has distinct eligibility requirements. Although propensity score matching balances measured confounders between groups, it cannot account for heterogeneity in the treatment. Additionally, the results of this study cannot be applied to other pregnant populations, because the authors' estimates rely on a specific, but undefined, distribution of weight-loss interventions between comparator groups.⁵

The treatment could be clarified by emulating a hypothetical randomized controlled trial in which participants are assigned to distinct treatment arms, including bariatric surgery, semaglutide, a well-defined exercise program, or a combination of these.⁶ In practice, the authors may consider the other regimens through matching, comparison of distributions, or sensitivity analyses.⁷

Although it may be difficult to account for all methods of weight-loss treatment in an observational study, we believe that clarifying the treatment definition is essential for clinicians and policymakers to interpret these results.

Financial Disclosure:

Jacob C. Kahrs has previously received funding as a graduate research assistant from Merck & Co., Inc as well as GSK plc. Additionally, he is affiliated with the Center for Pharmacoepidemiology at UNC, which is funded in part through unrestricted contributions from Center partners (AbbVie, Boehringer Ingelheim, GSK, Takeda, UCB, Sarepta, Astellas) and UNC Health. Kimi Van Wickle receives support from the National Heart, Lung, and Blood Institute (T32HL129982). Michelle T. Delahanty receives support from the National Institute of Child Health and Development (T32 HD52468). Mollie E. Wood received salary support from NIMHD (R01 MD011680), CDC (U01DD001231), the Kuni Foundation, and the PhRMA Foundation. She is affiliated with the Center for Pharmacoepidemiology at UNC, but does not receive salary support from CPE, and she provides occasional methods consulting to Center members on projects unrelated to the current work.

REFERENCES

1. Boller MJ, Xu F, Lee C, Sridhar S, Greenberg MB, Hedderson MM. Perinatal outcomes after bariatric surgery compared with a matched control group. *Obstet Gynecol* 2023;141:583–91. doi: 10.1097/AOG.0000000000005088 [PubMed: 36735357]
2. Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: weight loss and bariatric surgery. *Circ Res* 2016;118:1844–55. doi: 10.1161/CIRCRESAHA.116.307591 [PubMed: 27230645]
3. Akhter Z, Rankin J, Ceulemans D, Ngongalah L, Ackroyd R, Devlieger R, et al. Pregnancy after bariatric surgery and adverse perinatal outcomes: a systematic review and meta-analysis. *PLoS Med* 2019;16:e1002866. doi: 10.1371/journal.pmed.1002866 [PubMed: 31386658]
4. Hernán MA. Does water kill? A call for less casual causal inferences. *Ann Epidemiol* 2016;26:674–80. doi: 10.1016/j.annepidem.2016.08.016 [PubMed: 27641316]
5. Hernán MA, VanderWeele TJ. Compound treatments and transportability of causal inference. *Epidemiology* 2011;22:368–77. doi: 10.1097/EDE.0b013e3182109296 [PubMed: 21399502]
6. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *Am J Epidemiol* 2016;183:758–64. doi: 10.1093/aje/kwv254 [PubMed: 26994063]
7. Cole SR, Frangakis CE. The consistency statement in causal inference: a definition or an assumption? *Epidemiology* 2009;20:3–5. doi: 10.1097/EDE.0b013e31818ef366 [PubMed: 19234395]